Results 151 to 160 of about 1,925 (192)

Parent Perspectives on Nirsevimab for Their Newborn

Pediatrics
BACKGROUND In 2023, nirsevimab, a monoclonal antibody against respiratory syncytial virus (RSV), was approved in the United States to be given to infants to prevent bronchiolitis, a leading cause of pediatric hospitalizations.
Sarah, Hinderstein, Elena, Aragona, Jaspreet, Loyal   +2 more
openaire   +2 more sources

AN INTRODUCTION TO NIRSEVIMAB

Preventive Paediatrics
Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide.  It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness.
Ivana Kalanovic Dylag, Andrew Dylag
openaire   +1 more source

Race-Based Guidance and Nirsevimab

JAMA Pediatrics
This Viewpoint discusses the current Advisory Committee on Immunization Practices and American Academy of Pediatrics race-based guidelines on the administration of nirsevimab and suggested race-conscious revision of the current guidance.
Joshua T B, Williams, Florence, Wu
openaire   +2 more sources

Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case–control study

Lancet Regional Health - Europe, The
International audienceRespiratory syncytial virus (RSV) is the leading cause of lower-respiratory-tract infection in children. Nirsevimab, a monoclonal antibody against RSV, was implemented in a few countries in September 2023.
Corinne Levy, Andreas Werner, Zein Assad   +2 more
exaly   +2 more sources

Nirsevimab: A Review

Pediatric Allergy, Immunology, and Pulmonology
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in people of all ages and is the leading cause of hospitalization among infants in the United States. The year 2023 was exciting for RSV prevention. The Food and Drug Administration (FDA) approved 3 new tools for preventing severe lower respiratory tract RSV ...
openaire   +2 more sources

Balanced on the Biggest Wave: Nirsevimab for Newborns

Neonatal Network
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete
Christopher, McPherson, Christine R, Lockowitz, Jason G, Newland   +2 more
openaire   +2 more sources

Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children

Pediatrics
BACKGROUND AND OBJECTIVES Immunocompromised children may have increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI), potentially leading to prolonged hospitalization, intensive care, and death.
Joseph, Domachowske, Ulrika Wählby, Hamrén, Irfana, Banu, Roberta, Baronio, Bhanu, Basavaraju, Anthonet, Koen, Amanda, Leach, Vaishali S, Mankad, Pia S, Pannaraj, Pere, Soler-Palacin, Therese, Takas, Masaaki, Mori, Tonya, Villafana   +12 more
openaire   +2 more sources

Nirsevimab Administration During the Birth Hospitalization

Hospital Pediatrics
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of newborn hospitalization. In July 2023, nirsevimab, a monoclonal antibody to protect infants against RSV and reduce severe illness, was approved. Nirsevimab is the newest birth hospitalization immunization.
Shayda, Daneshvari, Philip, Lee, Sheri L, Nemerofsky   +2 more
openaire   +2 more sources

Practical Application of Nirsevimab Recommendations for Infants and Toddlers

Journal of Pediatric Health Care
Respiratory syncytial virus (RSV) is a common respiratory tract infection that causes bronchiolitis and pneumonia in infants and children. It is the leading cause of hospitalization of infants in the United States. Nirsevimab is a long-acting monoclonal antibody recommended for the prevention of severe disease in all infants under 8 months of age and ...
Carol Risko Radcliffe, Gabriella Akkawi, Rebecca A. Carson   +2 more
openaire   +2 more sources

Nirsevimab-alip

Clinical Therapeutics, 2023
openaire   +4 more sources